Escalating doses of clofarabine (CLO) for high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia post-MDS (sAML) failing azacitidine (AZA)

被引：0
|
作者：
Braun, T. [1 ]
Raffoux, E. [2 ]
Prebet, T. [3 ]
Stamatoullas, A. [4 ]
Brechignac, S. [1 ]
Dreyfus, F. [5 ]
Samey, B. [1 ]
Ades, L. [1 ]
Vey, N. [3 ]
Dombret, H. [2 ]
Fenaux, P. [1 ]
Gardin, C. [1 ]
机构：
[1] Univ Paris 08, Hop Avicenne, AP HP, Hematol,GFM, Bobigny, France
[2] Univ Paris 07, Hop St Louis, AP HP, Hematol,GFM, Paris, France
[3] Inst J Paoli I Calmettes, Hematol, GFM, F-13009 Marseille, France
[4] Ctr Henri Becquerel, GFM, Hematol, F-76038 Rouen, France
[5] Univ Paris 05, Hop Cochin, AP HP, Hematol,GFM, Paris, France
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70328-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-281
引用
收藏
页码：S149 / S149
页数：1
相关论文
共 50 条
  • [1] Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325)
    Braun, Thorsten
    Raffoux, Emmanuel
    Prebet, Thomas
    Brechignac, Sabine
    Stamatoullas, Aspasia
    Dreyfus, Francois
    Hebibi, Zehaira
    Ades, Lionel
    Vey, Norbert
    Dombret, Herve
    Fenaux, Pierre
    Cardin, Claude
    [J]. BLOOD, 2011, 118 (21) : 279 - 280
  • [2] Comparison of Transfusion Requirements in High Risk Myelodysplastic Syndromes (HR-MDS) and Secondary Acute Myeloid Leukemia (sAML) Treated with Azacitidine or Intensive Chemotherapy
    Alonso Nogues, E.
    Garcia Caro, M.
    Xicoy, B.
    Morgades, M.
    Linio, R.
    San Miguel, L.
    Gallardo, A.
    Prieto, M.
    Grifols, J.
    Ribera, J.
    [J]. TRANSFUSION, 2013, 53 : 189A - 189A
  • [3] Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)
    Kyo, Taiichi
    Yoshida, Noriaki
    Kyo, Kouhei
    Okatani, Takeshi
    Itagaki, Mitsuhiro
    Yuasa, Hiromi
    Iwato, Koji
    Asaoku, Hideki
    Katayama, Yuuta
    [J]. BLOOD, 2010, 116 (21) : 1209 - 1210
  • [4] A Phase II Study of Post-Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study
    Gardin, Claude
    Prebet, Thomas
    Bouabdallah, Krimo
    Caillot, Denis
    Guerci, Agnes
    Raffoux, Emmanuel
    Marolleau, Jean Pierre
    Pautas, Cecile
    Banos, Anne
    Himberlin, Chantal
    Taksin, Anne-Laure
    Pigneux, Arnaud
    Thomas, Xavier
    Jernival, Tony
    Vey, Norbert
    Dreyfus, Francois
    Chevret, Sylvie
    Dombret, Herve
    Fenaux, Pierre
    [J]. BLOOD, 2009, 114 (22) : 348 - 348
  • [5] Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)
    Xiao, Zhijian
    Chang, Chunkang
    Li, Qiubai
    Yan, Xiaojing
    Qin, Tiejun
    Tong, Hongyan
    Zhang, Yu
    Dai, Min
    He, Yanjie
    Weng, Jianyu
    Li, Jian
    Gao, Sujun
    Fu, Rong
    Wei, Xudong
    He, Aili
    Ren, Jinhai
    Wu, Tong
    Du, Xin
    Zhang, Yanni
    Xu, Ke
    Wang, Zhengyi
    Yang, Michelle
    Zhu, Andrew
    [J]. BLOOD, 2022, 140 : 8821 - 8822
  • [6] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    [J]. BLOOD, 2019, 134
  • [7] Myelodysplastic Syndrome Azacitidine - useful therapeutic option in high-risk MDS
    Arnheim, Katharina
    [J]. ONKOLOGIE, 2010, 33 (12): : 720 - 721
  • [8] Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly with azacitidine and gemtuzumab ozogamicin (GO)
    Nand, S.
    Godwin, J.
    Smith, S.
    Barton, K.
    Germano, E.
    Stiff, P.
    [J]. LEUKEMIA RESEARCH, 2007, 31 : S8 - S8
  • [9] An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).
    Mattiuzzi, Gloria
    Lahoti, Amit
    Salahudeen, Abdulla
    Ravandi, Farhad
    Cortes, Jorge
    Vu, Khanh
    Kantarjian, Hagop
    [J]. BLOOD, 2009, 114 (22) : 419 - 420
  • [10] Hospitalization rates in elderly, newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients treated with azacitidine.
    Ueda, Masumi
    Gupta, Divya
    Caimi, Paolo Fabrizio
    Creger, Richard
    Little, Jane
    William, Basem M.
    Lazarus, Hillard M.
    De Lima, Marcos J. G.
    Cooper, Brenda W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345